Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19 CAR T-Cell Therapy in Severe Refractory SLE
NCT06710717Phase 1Recruiting
- Sponsor
- Universiti Kebangsaan Malaysia
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Universiti Kebangsaan Malaysia. Primary endpoints: Rate of Adverse events at 24 months and SLEDAI Remission Rate at 28 weeks. Started Jan 2025; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06710717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710717.